CCMU
GRCL

Cheyne Capital Management (UK)’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Cheyne Capital Management (UK)’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-98,120
Closed -$226K – 59
2022
Q4 		$226K Buy
+98,120
New +$301K 0.39% 55

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Cheyne Capital Management (UK)'s GRCL Position: Q1 2023 in Review

Cheyne Capital Management (UK) sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2023, closing a stake of 98,120 shares — an estimated $226K sold.

Cheyne Capital Management (UK) first reported a position in GRCL in Q4 2022 and held it in 1 quarter. The position peaked at $226K in Q4 2022. 33 funds tracked by Wall St. Rank hold GRCL as of Q1 2023.

  • Cheyne Capital Management (UK) reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2023 after selling out during the quarter.
  • Cheyne Capital Management (UK) sold 98,120 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2023, an estimated $226K.
  • Cheyne Capital Management (UK) first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q4 2022 and held it in 1 quarter.
  • Cheyne Capital Management (UK)'s Gracell Biotechnologies Inc. American Depositary Shares position peaked at $226K in Q4 2022.
  • 33 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2023.

Based on Cheyne Capital Management (UK)'s 13F filing for Q1 2023, filed 3 May 2023.